A study of organic acid transporter mediated pharmacokinetic interaction between NXY-059 and cefuroxime.
AstraZeneca R&D, Södertälje, Medical Neuroscience, Södertälje, Sweden.
Matts
M
Kågedal
Dag
D
Nilsson
Gunilla
G
Huledal
Ingalill
I
Reinholdsson
Yi-Fang
YF
Cheng
Nils
N
Asenblad
David
D
Pekar
Olof
O
Borgå
D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000493:pharmacokinetics*; D001557:Benzenesulfonates / Q000009:adverse effects / Q000493:pharmacokinetics*; D002444:Cefuroxime / Q000009:adverse effects / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000493:pharmacokinetics*; D027361:Organic Anion Transporters / Q000502:physiology*
D000900:Anti-Bacterial Agents; D001557:Benzenesulfonates; D018696:Neuroprotective Agents; D027361:Organic Anion Transporters; C120851:disufenton sodium; D002444:Cefuroxime